Jaguar Health Deal History & Licensing Activity
Jaguar Health is a specialty pharma. Over the past three years, Jaguar Health has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Small Molecules
Focus Area
Infectious Disease
Jaguar Health Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Jaguar Health in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Mytesi and Canalevia-CA1 | Woodward Specialty, LLC | Small Molecules | Approved | license | Jan 12, 2026 |
| Mytesi and Canalevia-CA1 | Future Pak | Small Molecules | Approved | license | Jan 1, 2026 |
Jaguar Health Pipeline Focus
Therapeutic areas and modalities where Jaguar Health is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Jaguar Health's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Jaguar Health Licensing & Deal Activity
Jaguar Health is a specialty pharma company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Jaguar Health ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Jaguar Health include Infectious Disease (3 deals and trials), and Other (2 deals and trials). In terms of modality, Jaguar Health has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Jaguar Health and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Jaguar Health's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.